
Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer.
Episodes in this series
Panelists examine the SUNLIGHT trial, which evaluated trifluridine/tipiracil (FTD/TPI) alone vs in combination with bevacizumab. The addition of bevacizumab demonstrated enhanced outcomes, supporting its role in extending survival while maintaining tolerability.
The rationale for combining bevacizumab with FTD/TPI lies in its complementary mechanisms, offering potential synergy that translates to improved patient benefit.
They also note that real-world experiences largely align with trial data, reinforcing clinical confidence in the regimen’s effectiveness across diverse patient populations.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.